NSE filing, NSE: SAKAR. Summary written from the filing by ALFA Finder's alert engine.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹944.80
- Market cap
- ₹2,102 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 49.0×Sector 45.9×
- Promoter holding
- 51.70%-0.82% QoQ
- FII holding
- 12.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
- Call
- Guides 35% growth
Sakar Healthcare Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare Results Update
Sakar Healthcare reported Q2 FY27 revenue of ₹87.42 Cr and PAT of ₹11.31 Cr, up 149% YoY. EBITDA rose 114% to ₹24.35 Cr on strong oncology approvals and commercial supply commencement.
Sakar Healthcare Q2 FY27 Results: Net Profit ₹11.3 Cr, Up 151.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.3 Cr · +151.1% YoY
Sakar Healthcare Board Meeting Date
Sakar Healthcare has scheduled a board meeting for October 23, 2026, to approve its unaudited quarterly financial results for the period ended September 2026.
Sakar Healthcare Business Update
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.
Other other announcement announcements
All →Yaan Enterprises Other Announcement
Yaan Enterprises filed its quarterly shareholding pattern for the quarter ended 30 September 2026. Promoter and promoter group hold 70.65% of the 31,00,000 share capital.
Zen Technologies Other Announcement
Zen Technologies reported no QIP fund utilisation deviation for the quarter ended September 30, 2026. Rs.737.85 Crore of Rs.979.51 Crore raised is utilised per original objects.
Nanta Tech Other Announcement
Nanta Tech confirms no deviation in IPO proceeds utilisation against prospectus objects for the quarter ended 30 September 2026. Auditor certificate attached.
Midwest Other Announcement
Midwest Ltd filed its quarterly shareholding pattern for the quarter ended 30 September 2026. Promoters hold 77.12% of equity; public holds 22.88%.
Rhetan TMT Other Announcement
Rhetan TMT filed its quarterly shareholding pattern for the period ended 30 September 2026 under Regulation 31. Promoter and promoter group hold 62.12%, with no transaction or capital event described.
Yajur Fibres Other Announcement
Yajur Fibres Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026. The filing is routine SEBI Reg 31 disclosure with no transaction.